TY  - JOUR
AU  - Hermann, Wiebke
AU  - Sankutlu, Aleyna
AU  - Nabers, Lydia
AU  - Sehr, Tony
AU  - Trentzsch, Katrin
AU  - Donix, Markus
AU  - Reichmann, Heinz
AU  - Brandt, Daniel Moritz
AU  - Storch, Alexander
AU  - Ziemssen, Tjalf
TI  - Gait dysfunction as an early marker of phenoconversion in REM sleep behavior disorder.
JO  - Scientific reports
VL  - 16
IS  - 1
SN  - 2045-2322
CY  - [London]
PB  - Springer Nature
M1  - DZNE-2026-00181
SP  - 5614
PY  - 2026
AB  - Clinical isolated REM Sleep Behavior Disorder (iRBD) is a prodromal stage of α-synucleinopathies such as Parkinson's disease (PD). Longitudinal changes of gait as a marker of phenoconversion in iRBD have not been systematically evaluated yet. Therefore, twenty-one iRBD patients, nineteen matched healthy controls and fourteen PD patients (H</td><td width="150">
AB  - Y stage I - III) were assessed at baseline using a pressure-sensor walkway (GAITRite). While normalized gait velocity and walking endurance were significantly decreased in iRBD patients compared to controls, gait rhythm parameters such as single support further discriminated PD from iRBD and controls. IRBD patients at imminent risk of phenoconversion within the next 3.7 ± 0.6 years were distinguishable from non-converters by gait rhythm parameters such as single support. Since gait evaluation of our iRBD cohort showed promising results in predicting imminent phenoconversion, future multicenter trials should include gait analysis as an objective assessment of motor function to confirm our results.
KW  - Humans
KW  - REM Sleep Behavior Disorder: physiopathology
KW  - REM Sleep Behavior Disorder: diagnosis
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Parkinson Disease: physiopathology
KW  - Parkinson Disease: diagnosis
KW  - Aged
KW  - Gait: physiology
KW  - Case-Control Studies
KW  - Biomarkers
KW  - Gait Disorders, Neurologic: physiopathology
KW  - Gait Disorders, Neurologic: diagnosis
KW  - Gait dysfunction (Other)
KW  - Parkinson’s disease (Other)
KW  - Progression (Other)
KW  - REM sleep behaviour disorder (Other)
KW  - Α-synucleinopathies (Other)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41663457
DO  - DOI:10.1038/s41598-026-37925-w
UR  - https://pub.dzne.de/record/285159
ER  -